Figure 8 Investment Strategies LLC Purchases 18,380 Shares of GSK PLC Sponsored ADR $GSK

Figure 8 Investment Strategies LLC raised its position in GSK PLC Sponsored ADR (NYSE:GSK) by 90.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,686 shares of the pharmaceutical company’s stock after purchasing an additional 18,380 shares during the quarter. GSK accounts for approximately 1.8% of Figure 8 Investment Strategies LLC’s holdings, making the stock its 20th largest holding. Figure 8 Investment Strategies LLC’s holdings in GSK were worth $2,028,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in GSK in the 4th quarter valued at approximately $528,000. Dorsey Wright & Associates bought a new stake in GSK in the 1st quarter valued at approximately $2,522,000. Kahn Brothers Group Inc. bought a new stake in GSK in the 2nd quarter valued at approximately $8,305,000. Fisher Asset Management LLC boosted its position in GSK by 3.0% during the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after acquiring an additional 968,370 shares during the last quarter. Finally, Leuthold Group LLC acquired a new position in GSK during the 4th quarter worth approximately $4,922,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. Citigroup began coverage on shares of GSK in a research note on Friday, July 24th. They issued a “neutral” rating on the stock. Finally, Weiss Ratings cut shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $53.00.

GSK Stock Down 1.9%

GSK stock opened at $49.88 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The business has a 50 day moving average price of $51.70 and a two-hundred day moving average price of $53.20. The company has a market cap of $100.89 billion, a price-to-earnings ratio of 15.60, a P/E/G ratio of 1.95 and a beta of 0.35. GSK PLC Sponsored ADR has a twelve month low of $39.29 and a twelve month high of $61.69.

GSK (NYSE:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts anticipate that GSK PLC Sponsored ADR will post 4.83 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be issued a dividend of $0.4515 per share. The ex-dividend date is Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. GSK’s dividend payout ratio is presently 55.63%.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
• Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.